TCM
CTKB icon

Topline Capital Management’s Cytek Biosciences CTKB Stock Holding History

Topline Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.9M Sell
7,064,481
-377,985
-5% -$1.78M 5.1% 7
2025
Q4 		$37.6M Buy
7,442,466
+498,186
+7% +$2.31M 3.4% 10
2025
Q3 		$24.1M Buy
6,944,280
+1,713,020
+33% +$6.43M 4.14% 9
2025
Q2 		$17.8M Buy
5,231,260
+3,760,485
+256% +$12.5M 3.05% 12
2025
Q1 		$5.9M Buy
1,470,775
+1,234,179
+522% +$6.4M 1.35% 18
2024
Q4 		$1.54M Buy
+236,596
New +$1.41M 0.29% 29

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Topline Capital Management's CTKB Position: Q1 2026 in Review

Topline Capital Management reduced its Cytek Biosciences (CTKB) stake by 5.1% in Q1 2026, selling an estimated $1.78M and leaving 7,064,481 shares worth $30.9M. The position accounts for 5.1% of the portfolio, ranked #7.

Topline Capital Management first reported a position in CTKB in Q4 2024 and has held it in 6 quarters since. The position peaked at $37.6M in Q4 2025. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Topline Capital Management held 7,064,481 shares of Cytek Biosciences worth $30.9M as of Q1 2026.
  • Topline Capital Management sold 377,985 Cytek Biosciences shares in Q1 2026, an estimated $1.78M.
  • Cytek Biosciences made up 5.1% of Topline Capital Management's portfolio in Q1 2026, its #7 holding.
  • Topline Capital Management first reported a position in Cytek Biosciences in Q4 2024 and has held it in 6 quarters since.
  • Topline Capital Management's Cytek Biosciences position peaked at $37.6M in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Topline Capital Management's 13F filing for Q1 2026, filed 15 May 2026.